ProCE Banner Activity

VESPER: Phase III Trial of Perioperative Chemotherapy With Dose-Dense MVAC vs Gemcitabine + Cisplatin in Patients With Muscle-Invasive Bladder Cancer

Slideset Download
Conference Coverage
Among patients with muscle-invasive bladder cancer, dose-dense MVAC significantly improved the 3-year rate of PFS and time to progression vs gemcitabine plus cisplatin in the neoadjuvant setting.

Released: September 27, 2021

Expiration: September 26, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc